8-K: Disc Medicine Secures $200 Million Debt Financing to Advance Hematology Pipeline

Disc Medicine has secured a $200 million non-dilutive term loan facility from Hercules Capital to support its clinical development programs.

Summary

• Disc Medicine has entered into a loan agreement with Hercules Capital for up to $200 million in senior secured term loans.
• The initial advance of $30 million was funded on November 6, 2024.
• An additional $80 million is available at Disc's discretion through the second half of 2026.
• Up to $65 million is available upon achievement of certain performance milestones.
• A final $25 million tranche is available subject to lender approval.
• The loan matures on December 1, 2029, and has an interest-only period through December 1, 2028, which can be extended to December 1, 2029, upon achieving a specific milestone.
• The interest rate is a floating annual rate equal to the greater of 8.25% or the prime rate plus 1.75%.
• The company can reduce the cash interest rate by up to 2.00% per annum, with the reduced amount accruing as payment-in-kind (PIK) interest at a rate of 1.10 times the reduction amount.
• The loan is secured by a first-priority security interest in all tangible and intangible assets of the Borrower, excluding intellectual property.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful securing of a significant non-dilutive financing, which is expected to support the company's growth and development. The terms of the loan are also favorable, with an interest-only period and flexibility in accessing additional tranches.

Positives

• The non-dilutive financing strengthens Disc Medicine's financial position without diluting existing shareholders.
• The loan provides significant financial and operational flexibility for future capital formation.
• The funding can support the development of the company's entire pipeline, including bitopertin, DISC-0974, and DISC-3405.
• The interest-only period provides flexibility in managing cash flow.
• The loan structure allows for additional funding tranches to be accessed as the company achieves milestones.

Negatives

• The loan is secured by a first-priority security interest in all tangible and intangible assets, excluding intellectual property, which could pose a risk in case of default.
• The floating interest rate exposes the company to potential increases in borrowing costs if interest rates rise.
• The company is subject to a minimum cash covenant starting in 2027, which could restrict financial flexibility if not met.
• The final $25 million tranche is subject to lender approval, which introduces uncertainty.

Risks

• The company's ability to draw down additional tranches is contingent on achieving certain milestones.
• Failure to meet the minimum cash covenant could trigger an event of default.
• The floating interest rate could increase the cost of borrowing.
• The company's obligations under the loan agreement are secured by a first-priority security interest in its assets, excluding intellectual property.
• The company is subject to customary repayment and prepayment terms, affirmative and negative covenants, and events of default.

Future Outlook

The financing is intended to support key catalysts, including the initiation of a confirmatory study of bitopertin in EPP by mid-2025, a Phase 2 study of DISC-0974 in anemia of MF, a multiple dose study in anemia of NDD-CKD, and a Phase 2 study of DISC-3405 in PV. The company believes this financing provides optionality and strategic flexibility in future capital formation.

Management Comments

• Jean Franchi, Chief Financial Officer of Disc, stated that the financing strengthens the company's financial position and provides strategic flexibility.
• Bryan Jadot, Senior Managing Director and Group Head at Hercules Capital, expressed excitement to partner with Disc and support their next phase of growth.

Industry Context

This announcement reflects a trend of biotech companies seeking non-dilutive financing options to fund their clinical development programs. Hercules Capital is a well-known provider of debt financing in the life sciences sector, indicating a level of confidence in Disc Medicine's pipeline and potential.

Comparison to Industry Standards

• The loan structure with multiple tranches and milestone-based funding is common in the biotech industry, allowing companies to access capital as they achieve key development goals.
• The interest rate and terms are generally consistent with other venture debt financings in the life sciences sector, although the specific terms are tailored to Disc Medicine's situation.
• Comparable companies that have secured similar debt financings include clinical-stage biopharmaceutical companies with promising pipelines and near-term catalysts.
• The use of a non-dilutive financing option is a strategic move to avoid diluting existing shareholders, which is a common goal for companies in this sector.

Stakeholder Impact

• Shareholders: The non-dilutive financing is positive as it avoids dilution of existing equity.
• Employees: The financing provides financial stability and supports the company's growth, which could lead to job security and opportunities.
• Customers: The financing supports the development of new treatments, which could benefit patients suffering from serious hematologic diseases.
• Creditors: The loan agreement establishes a new creditor relationship with Hercules Capital.
• Suppliers: The financing could lead to increased business activity and demand for supplies.

Next Steps

• Disc Medicine will use the funds to support the development of its pipeline, including the initiation of a confirmatory study of bitopertin in EPP by mid-2025.
• The company will continue to advance its Phase 2 study of DISC-0974 in anemia of MF, a multiple dose study in anemia of NDD-CKD, and a Phase 2 study of DISC-3405 in PV.
• The company will file additional details of the loan agreement with the Securities and Exchange Commission on a Current Report on Form 8-K.

Key Dates

Keywords

debt financing, term loan, non-dilutive, Hercules Capital, biopharmaceutical, hematologic diseases, bitopertin, DISC-0974, DISC-3405, clinical development, erythropoietic protoporphyria, myelofibrosis, chronic kidney disease, polycythemia vera